Related MeSH Hierarchy (5)
Diseases [C] » Neoplasms [C04] » Precancerous Conditions » Smoldering Multiple Myeloma
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Blood Protein Disorders » Hypergammaglobulinemia » Smoldering Multiple Myeloma
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Blood Protein Disorders » Paraproteinemias » Smoldering Multiple Myeloma
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Hypergammaglobulinemia » Smoldering Multiple Myeloma
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Paraproteinemias » Smoldering Multiple Myeloma
Description
An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA. MeSH
Hierarchy View
Approved Indicated Drugs (1)
Phase 2 Indicated Drugs (21)
Phase 1 Indicated Drugs (2)
Other Experimental Indicated Drugs (2)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (37)
Organization Involved with Phase 1 Indications (7)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
